NCT00069238View on ClinicalTrials.gov

Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

September 19, 2003

Primary Completion Date

June 11, 2009

Study Completion Date

March 17, 2021

Conditions
Lymphoma, T-CellLymphoma, Extranodal NK-T-Cell
Interventions
BIOLOGICAL

Alemtuzumab (Campath)

Alemtuzumab (Campath) followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) every 3 weeks for up to 6 cycles.

DRUG

EPOCH

Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) + Alemtuzumab (Campath) every 3 weeks for up to 6 cycles.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00069238 - Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas | Biotech Hunter | Biotech Hunter